Cytogenetic risk stratification in chronic myelomonocytic leukemia. - Wikidata - wikimedia - TriplyDB

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

http://www.wikidata.org/entity/Q34612592

about

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia MDS prognostic scoring systems – past, present, and future Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.An evolutionary perspective on chronic myelomonocytic leukemia.Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.CMML: Clinical and molecular aspects.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool.Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

P2860

Q26768600-A865DFEB-D478-48F3-9964-101721139222 Q28082460-00AB5563-5449-4D46-BDAD-C34C5200E4C4 Q28307278-659D85CF-55BE-4F1E-8A05-EA9B51E58F6B Q30274942-A3567CB5-F6AF-4F4A-998F-5E7DCDBDD5A6 Q30420638-A52799C1-874C-45EA-9CEE-46AEF55CD145 Q33406648-42157E5C-AC96-41C9-8707-3CE2CF78FF25 Q33442672-A89052B5-151A-477A-878F-85AF855A4AB0 Q33600822-F2EEC354-B19E-497C-A5BE-2D8348B62CB6 Q33800102-EC80C53E-129F-4331-B8F4-BA6414FAFCE3 Q34157339-0EDC762B-F36F-42C2-8F74-B5C9BBF6BE42 Q34393208-64E18E99-6944-4077-A0A9-D289AD3E4BBB Q34637945-AB3B4362-7BB4-482E-9EE8-C11C5DA77FDA Q35162458-DD5BB583-8722-4D6F-A2D8-FE0CB1D8402A Q35654081-930FEE1D-758F-47F8-9AAA-741FCB8FB0EE Q35924710-5F1DF96D-EC17-43C9-86BB-D1AF3E905173 Q36163825-2B34B15D-97BA-40F5-B035-BF76915DD7D1 Q36548070-80C1426B-D960-4019-8C91-831BB770AFF7 Q36708989-3B3F1666-888C-4382-8E9C-D0965670837C Q36876853-1DB5D39C-E2D2-4E3A-9336-7DE435A209FC Q36967029-10D3D62F-7C54-4ED2-B1BB-D5AF3BA44C3C Q37235671-0B31D1A3-D0E6-4633-877B-FEFA6D3E9CE8 Q37349392-429E6E06-3319-49D3-B6E5-2CA9727D718A Q37636744-51DE40C4-3487-4CBB-8245-44D852811FBA Q37993420-CAC0B998-B594-4C2E-8814-F93FD55DC9E1 Q38012085-2CF322F9-3899-43BD-ABA9-1D3030229C27 Q38096235-222BEBFC-2508-45B1-ADA9-DBDC5914D626 Q38107912-59DD5575-EAF1-47AA-938B-7A7C14054621 Q38130476-E9BB50A4-66D4-4C90-98A9-A1BBD8652E89 Q38134374-F4859C2E-00ED-4763-BCA4-CA966E244982 Q38236642-A7FB3147-568D-47F3-AA1A-43522A04A1B2 Q38241774-545C25D3-7459-419E-B920-3FD2E264F48A Q38540013-2B3D6D09-82DF-4949-B987-24AF46356F55 Q38603384-31410A49-6F37-4514-9D1F-B7FFA931C01B Q38644826-66C9AE8B-7F94-4C55-A508-C223D187A9FE Q38689508-E37F5271-CBBF-4072-82EE-A758E34247ED Q38835771-E5D107D2-4B21-49F0-AD23-8AB9510DA57F Q38859646-16C3B219-5EA5-41E0-9041-3EC332C9B549 Q39100115-CCB573A5-271F-405D-8572-CD6FEDA88468 Q41176344-2FF8A6D5-BC3D-4091-AD86-C590A1454FE3 Q41183059-63432D27-A5E8-41A8-A2A2-CF6E9FA41465

P2860

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

http://www.wikidata.org/entity/Q34612592

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@ast

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@en

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@nl

type

label

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@ast

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@en

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@nl

prefLabel

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@ast

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@en

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

@nl

P1433

Q34612592-7EDCDE7A-DA66-4223-974C-A9A091D4A361

P1476

Q34612592-983B0C16-CE4B-4D63-83B0-FCC9F6515877

P2093

Q34612592-044F8EF1-2FA1-4ADA-88A7-9FD63D0EEAB5

Q34612592-0F7A2855-9732-4D37-AF5D-01C14CE403C2

Q34612592-0FBD1690-3ECB-4600-8F7F-C020CD13F0B1

Q34612592-35C58018-76C8-4B95-91AB-84E21236AB57

Q34612592-3B6AA7D2-957D-4138-A4C1-A320D6F7143F

Q34612592-43378AE4-4146-4FF0-8A2D-B04202A14707

Q34612592-43B408FF-4EDE-412C-949D-71050D323DC9

Q34612592-50B0C076-E901-48A4-9F44-0B8FB81B1AA3

Q34612592-5577F384-EE91-4408-96A9-DDA27C668FA9

Q34612592-6264BD63-0C47-4790-A00C-556171FA8F76

P2860

Q34612592-019E07CB-ABE1-4ED5-A09F-64E4F0F6545B

Q34612592-0E0FFA33-6359-4902-A3EA-FD7B68E91092

Q34612592-1020117D-9715-4A1E-A459-F17CF91ED687

Q34612592-18E51170-9399-4CFB-BB48-4957CC7B7447

Q34612592-3E5ACF5E-4767-4F19-B952-497075F37EA2

Q34612592-44FBA240-A172-4BCC-9DE3-3DE5AFE47296

Q34612592-66820CEC-AA3F-40CE-BE3D-3B82AD0A4303

Q34612592-8CEDB566-CB61-4980-9481-3BBDFEB28D14

Q34612592-C06F73A0-64D1-4B63-B2D3-876F745B0933

Q34612592-D261D9A6-70AE-4F27-820F-E470DEFCAC9D

P304

Q34612592-0F81682E-B528-4F7F-9186-77B94DCDCEE4

P31

Q34612592-64C7973A-2CDA-4247-AE16-2DF1BEC1479C

P356

Q34612592-57131D49-4566-40A5-B81B-1DC73A4840B0

P433

Q34612592-D69D556D-3E71-4AF2-8F4B-5E50F316DE8E

P478

Q34612592-1B1A4345-A0E6-4F2C-875C-237817DA6F92

P50

Q34612592-9B19A00C-D9BD-4E5B-AD0F-A76154F9F9D2

Q34612592-A53B26D0-1F04-4F5E-AD31-78F070FFFA47

Q34612592-B2208F59-540F-44F3-9D19-1E165816D212

Q34612592-B49D3B55-A392-419D-80FF-38DEF5D923B5

Q34612592-F41E097D-0937-43F5-94AE-B6F078EE57C3

Q34612592-FABFECD7-8C69-40B0-A1F3-F607519CEB41

P577

Q34612592-AD4C8147-3252-4AA6-89BA-FF000BE61562

P5875

Q34612592-C8D18492-9A72-4355-BD49-DE76A4D8D259

P698

Q34612592-63161980-0D74-4D79-9818-2DCC237D4802

P921

Q34612592-B53C0FED-62E5-43ED-AB29-B5634E06D03B

P932

Q34612592-272185FA-58DB-42A6-98EF-F83C22695CE1

P356

HAEMATOL.2010.030957

P1433

P1476

Cytogenetic risk stratification in chronic myelomonocytic leukemia

@en

P2093

Benet Nomdedeu

http://www.w3.org/2001/XMLSchema#string

Carmen Pedro

http://www.w3.org/2001/XMLSchema#string

Consuelo del Cañizo

http://www.w3.org/2001/XMLSchema#string

Dolors Costa

http://www.w3.org/2001/XMLSchema#string

Elisa Luño

http://www.w3.org/2001/XMLSchema#string

Esperanza Such

http://www.w3.org/2001/XMLSchema#string

Felix Carbonell

http://www.w3.org/2001/XMLSchema#string

Fernando Ramos

http://www.w3.org/2001/XMLSchema#string

Francesc Solé

http://www.w3.org/2001/XMLSchema#string

Javier Bueno

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

Proposals for the classification of the myelodysplastic syndromes

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

International scoring system for evaluating prognosis in myelodysplastic syndromes

Prognosis of chronic myelomonocytic leukemia.

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.

IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.

Molecular basis of myelodysplastic/myeloproliferative neoplasms.

P304

375-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2010.030957

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Guillermo F Sanz

Santiago Bonanad

P577

2010-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49637741

http://www.w3.org/2001/XMLSchema#string

P698

21109693

http://www.w3.org/2001/XMLSchema#string

P921

P932

3046268

http://www.w3.org/2001/XMLSchema#string